Journal of Thyroid Cancer

The Open Access Pub has the reputation for quick reviewing and publishing original research articles. The editorial boards of our journals have many dedicated and reputed scientists as editorial members. Their support helps many researchers from all countries to enhance their research between scientists of various communities. This platform plays a crucial role in promoting science networks and exchanges.

Thyroid Cancer-Radiology-Frederik Anton Verburg


Senior physician,
Clinic for Nuclear Medicine,
Department of Nuclear Medicine.

0241 80 88742, +49/(0)241/803 66 19

Send an Email

Frederik Anton Verburg


52425 Jülich, Germany.
RWTH University Hospital Aachen
Department of Nuclear Medicine
Pauwelsstraße 30, 52074 Aachen, Germany

Research Interests:

Radiology, Surgery, Otolaryngology, Plastic Surgery, Neuroradiology, Oral and Maxillofacial Surgery, Oncology, Internal Medicine (General Medicine).


1998-2004: Medical School, UMC Utrecht, Utrecht, the Netherlands.
2005-2007: Assistent physician, UMC Utrecht, Department of Nuclear Medicine, Utrecht.


  1. Prognostic significance of successful ablation with radioiodine of differentiated thyroid cancer patients.
  2. Recombinant thyrotropin use in children and adolescents with differentiated thyroid cancer: a multicenter retrospective study.
  3. Combination of peptide receptor radionuclide therapy with fractionated external beam radiotherapy for treatment of advanced symptomatic meningioma.
  4. A comparison of prognostic classification systems for differentiated thyroid carcinoma
    Frederik A Verburg.
  5. No survival difference after successful (131)I ablation between patients with initially low-risk and high-risk differentiated thyroid cancer.
  6. Dosimetry-guided high-activity (131)I therapy in patients with advanced differentiated thyroid carcinoma: initial experience.
  7. The association between multinodular goiter and thyroid cancer.
  8. (131)I therapy in patients with benign thyroid disease does not conclusively lead to a higher risk of subsequent malignancies.
  9. The absorbed dose to the blood is a better predictor of ablation success than the administered 131I activity in thyroid cancer patients.
  10. Intratracheal growth of recurrent benign goiter.